A 45-year-old woman with systemic sclerosis presents with progressive dyspnea. Hemodynamic catheterization confirms pulmonary arterial hypertension (mPAP 35 mmHg, PCWP 12 mmHg, PVR 4.2 Wood units). She undergoes a six-minute walk test as part of risk stratification. The distance marked **A** in the diagram (<332 m) is achieved. Which of the following best describes the prognostic significance of this finding?
A. Reflects poor effort during testing and should be repeated before treatment decisions are made
B. Suggests mild disease suitable for monotherapy with a phosphodiesterase-5 inhibitor alone
C. Indicates low-risk disease and excellent long-term survival without pharmacotherapy
D. Predicts increased mortality and places the patient in the high-risk category requiring intensive combination therapy
Explanation
Why "Predicts increased mortality and places the patient in the high-risk category requiring intensive combination therapy" is right
The six-minute walk distance (6MWD) is the most widely used and validated prognostic marker in pulmonary arterial hypertension. A 6MWD <332 meters is incorporated into the ESC/ERS 2022 risk stratification and predicts increased mortality, placing the patient in the high-risk category (high-risk defined as 6MWD <165 m in some schemas, but <332 m indicates poor prognosis). This finding mandates intensive treatment, typically with combination therapy (e.g., ambrisentan + tadalafil) as demonstrated in the AMBITION trial, which showed 50% reduction in clinical events with dual therapy compared to monotherapy (Harrison's 21e Ch 283; ESC/ERS PH Guidelines 2022).
Why each distractor is wrong
"Indicates low-risk disease and excellent long-term survival without pharmacotherapy": This reverses the prognostic significance. Low-risk disease is defined by 6MWD >440 m. A distance <332 m is associated with poor prognosis and requires aggressive pharmacotherapy, not observation alone.
"Suggests mild disease suitable for monotherapy with a phosphodiesterase-5 inhibitor alone": Monotherapy is reserved for low-risk or selected intermediate-risk patients. A 6MWD <332 m indicates high-risk disease requiring combination therapy (prostacyclin pathway agent + PDE5 inhibitor ± endothelin receptor antagonist), not monotherapy.
"Reflects poor effort during testing and should be repeated before treatment decisions are made": While effort is monitored during 6MWT (via Borg dyspnea scale, heart rate, and oxygen saturation), a 6MWD <332 m in a symptomatic PAH patient with confirmed hemodynamic criteria is a valid prognostic marker and should not be dismissed as poor effort. Treatment decisions are based on this result.
High-YieldNEET PG
6MWD <332 m = high-risk PAH = combination therapy (dual/triple); 6MWD >440 m = low-risk = monotherapy acceptable.
Harrison's 21e Ch 283; ESC/ERS PH Guidelines 2022
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
